TNGX Q4 2021 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-37.5% YoY

Gross Profit

$5M89.9% margin

Operating Income

-$22M-384.6% margin

Net Income

-$22M-385.7% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-15.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$500M

Total Liabilities

$155M

Stockholders' Equity

$345M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$9M	-37.5%
Gross Profit	$5M	$9M	-41.0%
Operating Income	-$22M	-$9M	-146.0%
Net Income	-$22M	-$9M	-148.7%

Revenue Segments

Collaboration Revenue

$6M100%